Fabre-Kramer Pharmaceuticals
 |
Houston, Texas | |
Key people | Stephen Kramer (CEO) Ed Koehler (Executive Vice President, CFO) |
|---|---|
| Products | Travivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD |
| Website | www.fabrekramer.com |
Fabre-Kramer Pharmaceuticals is a
FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,[1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.[2]
The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[3][4][5]
In 2007, Fabre-Kramer Pharmaceuticals along with
GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.[6]
References
- ^ "Pipeline – Fabre-Kramer Pharmaceuticals, Inc". Archived from the original on March 30, 2023. Retrieved 2023-03-30.
- ^ "Product Pipeline". Fabre Kramer Pharmaceuticals. Archived from the original on 2011-11-11. Retrieved 2011-10-16.
- PMID 21883948.
- PMID 21707926.
- PMID 21324094.
- ^ Lewcock, Anna (November 5, 2007). "GSK, Fabre-Kramer lose out on antidepressant". outsourcing-pharma.com. Archived from the original on September 10, 2023. Retrieved 2020-05-11.
External links